# A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

> **NCT07589764** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Duke University** · enrollment: 100 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis ALS

## Interventions

- **DRUG:** β-hydroxy-β-methylbutyrate (HMB)

## Key facts

- **NCT ID:** NCT07589764
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07589764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07589764, "A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07589764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*